Valeo Pharma Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Al Moghaddam

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

CEO

Al Moghaddam (57 yo)

less than a year

Tenure

Mr. Al Moghaddam, B. Com. CMA had been a Director at Valeo Pharma Inc. since March 21, 2024 until June 2024 and served as its Chief Development Officer since June 2024 until August 2024 and serves as its C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kyle Steiger	Senior VP & Chief Commercial Officer	2.3yrs	CA$388.21k	0.020% $ 909.4
Al Moghaddam	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Pascal Tougas	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Frédéric Dumais	Director of Communications & Investor Relations	no data	geen gegevens	0.26% $ 12.1k
Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	no data	geen gegevens	0% $ 0
Jean Fournier	Head of Ophthalmology Business Unit	2.3yrs	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

Ervaren management: Het managementteam van VPHI.F wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Raich	Independent Director	less than a year	geen gegevens	0.18% $ 8.2k
Richard MacKay	Chairman of the Advisory Board & Director	15.8yrs	geen gegevens	16.44% $ 760.8k
Steven Saviuk	Chairman	21.7yrs	CA$466.29k	0.18% $ 8.5k
Marc Leger	Independent Non-Executive Director	2.6yrs	geen gegevens	2.36% $ 109.3k
Richard Lajoie	Independent Director	less than a year	geen gegevens	geen gegevens
Charles Bisaillon	Independent Director	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VPHI.F wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Valeo Pharma Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors

Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors

Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Announces Chief Financial Officer Changes

Recent updates

Valeo Pharma Inc. to Report Q3, 2024 Results on Sep 12, 2024

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. Appoints Al Moghaddam as Chief Development Officer and Consequently Steps Down from its Board of Directors

Valeo Pharma Inc. to Report Q2, 2024 Results on Jun 13, 2024

Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors

Valeo Pharma Inc. to Report Q1, 2024 Results on Mar 14, 2024

Valeo Pharma Inc., Annual General Meeting, Apr 25, 2024

Valeo Pharma Inc. Announces Board Changes

Valeo Pharma Inc. to Report Q4, 2023 Results on Jan 29, 2024

Valeo Pharma Inc. Announces Chief Financial Officer Changes

Valeo Pharma Inc. Announces Chief Financial Officer Changes

Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of Directors

Valeo Pharma Inc. to Report Q3, 2023 Results on Sep 13, 2023

Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement Québec

Valeo Pharma Inc. Announces Board Appointments

Valeo Pharma Inc. to Report Q2, 2023 Results on Jun 13, 2023

Valeo Pharma Obtains Public Reimbursement for Onstryv in Quebec

Valeo Pharma Announces Filing of New Drug Submission-Covid 19 with Health Canada for Sabizabulin for the Treatment of Hospitalized Covid-19 Patients

Valeo Pharma Inc. to Report Q4, 2022 Results on Jan 30, 2023

Valeo Pharma Inc. Announces Stepping Down of Frederic Fasano as President and Chief Operating Officer

Valeo Pharma Inc. Revises Revenue Guidance for the Fourth Quarter of 2022

Valeo Pharma Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Valeo Pharma Inc. to Report Q3, 2022 Results on Sep 13, 2022

Valeo Pharma Announces Executive Appointments

Valeo Pharma Inc. to Report Q2, 2022 Results on Jun 14, 2022

Valeo Pharma Inc., Annual General Meeting, Apr 27, 2022

Valeo Pharma Inc. to Report Q4, 2021 Results on Feb 28, 2022

Valeo Pharma's Hespercotm Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted for Publication

Valeo Pharma Inc. announced that it expects to receive CAD 20 million in funding from Investissement Québec, Investment Arm and other investors

Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™

Valeo Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

Valeo Pharma Inc. Announces Commercial Launch of Enerzair Breezhaler and Atectura Breezhaler

Valeo Pharma Inc. Announces Outlook for Its Second Quarter Ended April 30, 2021

Valeo Pharma Inc. announced that it has received CAD 6.645 million in funding

Valeo Pharma Inc. announced that it expects to receive CAD 4 million in funding

Valeo Pharma Inc., Annual General Meeting, Apr 28, 2021

Valeo Pharma Inc. to Report Q4, 2020 Results on Feb 24, 2021

Valeo Pharma Inc. and Ingenew Pharma Inc. Announce HespercoTM Capsules

Valeo Pharma Appoints Frederic Fasano to the Newly Created Position of President and Chief Operating Officer

Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™

Valeo Pharma Announces Amikacin Approval in Canada and U.S. Launch of Ethacrynate Sodium

Valeo Pharma Announces That Hesperco™ Has Started Shipping

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd